Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annabel Helga Sophie Alig

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Ochsner Journal|September 16, 2024
Recurrent Intracranial Ewing SarcomaSoo Ann Yap, Annabel Helga Sophie Alig, Alena Annbalou Hasenburg, et al.
Plos One|July 14, 2022
Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patientsMichaela Barnikel, Annabel Helga Sophie Alig, Sofia Anton, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2023
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trialAlexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, et al.
Frontiers in Oncology|March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI TrialAnnika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
International Journal of Cancer|July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)Arndt Stahler, Beeke Hoppe, Il-Kang Na, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Ochsner Journal|September 16, 2024
Recurrent Intracranial Ewing SarcomaSoo Ann Yap, Annabel Helga Sophie Alig, Alena Annbalou Hasenburg, et al.
Plos One|July 14, 2022
Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patientsMichaela Barnikel, Annabel Helga Sophie Alig, Sofia Anton, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2023
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trialAlexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, et al.
Frontiers in Oncology|March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI TrialAnnika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
International Journal of Cancer|July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)Arndt Stahler, Beeke Hoppe, Il-Kang Na, et al.
Pageof 1